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license (http://creativegated the possible added value of monoaminergic compounds to the standard cerebrospinal fluid
(CSF) Alzheimer’s disease (AD) biomarkers. Particularly, regarding the AD versus dementia with
Lewy bodies (DLB) comparison, monoamines or their metabolites might have added discriminative
value as there is a more severe neuropathological burden in the locus coeruleus of DLB patients, the
principal site of noradrenaline synthesis.
Methods: We applied enzyme-linked immunosorbent assay (ELISA) to analyze CSF amyloid b pep-
tide of 42 amino acids, total tau, and tau phosphorylated at threonine 181, in patients with AD, fron-
totemporal dementia, DLB/Parkinson’s disease dementia, and controls. Reversed-phase high-
performance liquid chromatography with electrochemical detection was implemented to studymono-
amine and metabolite levels in CSF and serum. Stepwise forward conditional logistic regression and
receiver operating characteristic (ROC) curve analyses were performed to assess the diagnostic ac-
curacy of these newly fitted models containing the most discriminative indicators of disease status.
Results: Most significant differences in CSF and serum were confined to the noradrenergic system.
More specifically, CSF 3-methoxy-4-hydroxyphenylglycol (MHPG) levels were higher, whereas
serum MHPG levels were lower, in DLB patients compared with all other groups. Addition of CSF
and serum MHPG levels to the CSFAD biomarker panel significantly increased diagnostic accuracy
between DLB/Parkinson’s disease dementia and AD. Interestingly, a model only including CSF and
serum MHPG without the classic AD biomarker panel reached similar area under the curve values.
Discussion: We hypothesize that varying degrees of neuronal loss in the locus coeruleus of DLB/Par-
kinson’s disease dementia versus AD patients result in differentially altered MHPG levels, making
this metabolite a valuable biomarker.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: MHPG; Biomarkers; Alzheimer’s disease; Dementia with Lewy bodies; Monoamines; Diagnostic accuracy;RP-HPLC-ECD.
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Alzheimer’s disease (AD) and associated neurodegenera-
tive brain disorders remain an important health-care burden
[1]. Recent findings from the Alzheimer’s Association indi-
cate that in 2015, 46.8million people suffered from dementiaimer’s Association. This is an open access article under the CC BY-NC-ND
gen from ClinicalKey.com by Elsevier on March 29, 2018.
opyright ©2018. Elsevier Inc. All rights reserved.
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next couple of decades [2], giving rise to even higher health
strategies. Early detection of this neurocognitive disorder,
combined with treatment strategies in the initial stages of
the disease could aid in its reduction [3,4].
Although current cerebrospinal fluid (CSF) biomarkers for
AD diagnosis (amyloid b [Ab1–42], total tau (T-tau), and tau
phosphorylated at threonine 181 [P-tau181P]), as comprised
in the International Working Group-2 criteria [5], are widely
used in clinical research, they still bring about several chal-
lenges. As such, they lack specificity to accurately discrimi-
nate between AD and dementia with Lewy bodies (DLB),
which is especially complicated by the presence of AD co-
pathology in patients with DLB [6]. Thus, apart from shared
clinical symptoms, some dementia types can also share a com-
mon etiology. Because overlapping concentrations exist in
CSF T-tau and P-tau181P between AD, frontotemporal demen-
tia (FTD),DLB, and vascularAD [7], current diagnostics often
require additional imaging investigations for differential de-
mentia diagnosis. Another pitfall associated with CSF bio-
markers is that their diagnostic performance decreases with
age [8]. Given the aforementioned complications and the prac-
tical difficulties associated with CSF sampling, the search for
efficient blood biomarkers is imperative [9,10]. Nevertheless,
variability of the distinct blood constituents involves
supplementary challenges concerning reproducibility of
biomarker analysis. In addition, questions arise about the
applicability of blood biomarkers as the blood compartment
is not in direct contact with the central nervous system and
might therefore inaccurately reflect changes in disease
progression [10]. Moreover, it was shown that plasma and
CSF Ab1–42 levels did not correlate in either patients with
AD, non-AD,mild cognitive impairment, and control subjects
(CONTR) [11].Although a recently published article provided
the first evidence for plasma neurofilament light as a potential
blood biomarker for AD [12], such a blood biomarker for
discrimination between AD and non-AD cases, to the best of
our knowledge, has not been identified nor validated yet.
Recent studies, however, indicate that monoaminergic
neurotransmitter profiles could represent an added value in
improving etiological dementia diagnosis [13]. One of the first
indications of this hypothesiswas provided byAerts et al., who
proved that addition of CSF 3-methoxy-4-
hydroxyphenylglycol (MHPG), a main metabolite of the
monoamines adrenaline (A) and noradrenaline (NA) that
aids in indication of central noradrenergic activity [14], to
the classical biomarker profile of AD, could increase both
sensitivity and specificity for the discrimination between AD
and DLB [15,16]. This hypothesis might be further
strengthened by the notion that distinct MHPG levels
between AD and DLB patients were observed in eight out of
11 brain regions, with DLB patients demonstrating
significantly reducedMHPG levels [13]. Other studies investi-
gating monoamine neurotransmitter levels in brain tissue
equally gave rise to the awareness that AD and FTD differ in
serotonergic and noradrenergic neurotransmitter contentDownloaded for Anonymous User (n/a) at Rijksuniversiteit Gronin
For personal use only. No other uses without permission. C[17,18], while an earlier study reported that CSF MHPG
levels were considerably higher in FTD patients than those
in AD patients [19]. It was also noted that CSF NA and
MHPG levels were increased in patients with advanced AD
as compared with subjects suffering from moderate AD or
CONTR, suggesting hyperactivity of the noradrenergic system
in the end stage of the disease [20]. Furthermore, extensive ev-
idence demonstrates that the locus coeruleus (LC), the main
NA-producing nucleus in the brain, is severely affected by
Lewy pathology in Parkinson’s disease dementia (PDD) [21]
and associated with severe cell death which might affect the
dopaminergic nigrostriatal pathway through loss of noradren-
ergic innervation [22–25]. This Lewy pathology in PDD has
even been shown to precede the appearance of a-synuclein
inclusions and neuronal loss in the dopaminergic substantia
nigra [21,26–31], indicating an undeniable role of
noradrenergic deficits in PDD. Interestingly, MHPG easily
passes the blood–brain [32] and blood-CSF [33] barrier. Tak-
ing into account all of theabove, it appears thatmonoaminergic
systems are indeed differentially implicated in distinct demen-
tia subtypes and could potentially serve as predictive markers.
Accordingly, this study aimed at identifying predictive
monoamine biomarkers in both CSF and serum derived
from patients suffering from AD, FTD, DLB/PDD, age-
matched CONTR, and young control (Y-CONTR) subjects.
We hypothesized that these fluid monoamine markers, espe-
cially with regard to MHPG, could add significantly to the
classical CSF AD biomarker panel, thus increasing diag-
nostic accuracy.2. Materials & methods
2.1. Study population
Paired CSF-serum samples derived from patients with
probable AD (n 5 52), FTD (n 5 59), DLB (n 5 39), PDD
(n 5 14), as well as CONTR (n 5 88) and Y-CONTR
(n 5 32), were selected from the Biobank of the Institute
Born-Bunge. All patients included in the AD, FTD, DLB,
PDD, and Y-CONTR groups were included in a prospective,
longitudinal study on neuropsychiatric symptoms [34] be-
tween 2001 and 2011 and originally recruited at the Memory
Clinic of the Hospital Network Antwerp Middelheim (ZNA)
and Hoge Beuken as part of their diagnostic clinical workup.
At inclusion, subjects underwent neuropsychological assess-
ment and behavioral analysis as described earlier [34]. If con-
sented patients died, brain autopsy was performed within
6 hour postmortem. The left hemisphere was frozen at
280C, whereas the right hemisphere was fixated in parafor-
maldehyde (12%) for neuropathological examination, which
was performed as described earlier [13,17]. None of the age-
matched CONTR nor Y-CONTR suffered from neurological
disease. In addition, CONTR were excluded in case of psy-
chiatric antecedents or suspicion of central nervous system
pathology. Thus, the CONTR group consisted of patients
requiring lumbar radiculography as they suffered fromgen from ClinicalKey.com by Elsevier on March 29, 2018.
opyright ©2018. Elsevier Inc. All rights reserved.
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system disorders, and patients with subjective complaints
which were not due to disorders of the central nor the periph-
eral nervous system [35]. Finally, the study was approved by
the Medical Ethical Committee of the Middelheim General
Hospital (Antwerp, Belgium; approval numbers 2805 and
2806) and conducted in compliance with the Helsinki Decla-
ration.
2.2. CSF and serum sampling
Sampling of CSF was performed according to Vermeiren
et al. [36]. In short, a lumbar puncture was performed at the
L3/L4 or L4/L5 intervertebral space between 8.00 and 10.00
AM. Patients and CONTR fasted overnight and abstained
from smoking for at least 12 hours. In total, 16.5 mL CSF
was collected in five fractions using polypropylene vials as
described by Engelborghs et al. [35].
Total blood was sampled into two serum gel tubes coated
with clotting activator (S-Monovette 7.5 mL Z-gel [Sarstedt,
N€umbrecht, Germany]) and centrifuged at 3000 rpm for
10 minutes. Serum aliquots were subsequently distributed
to marked polypropylene vials and frozen in liquid nitrogen.
Of note, part of the CONTR group (n 5 43) followed the
protocol specified previously (i.e., matched CSF-serum sam-
ples after overnight fasting) [34], whereas serum-only sam-
ples of the remaining 45 CONTR were obtained at different
time points and under a distinct clinical setting.
All samples were stored in the Biobank of the Institute
Born-Bunge at 280C.
2.3. CSFAb1–42, T-tau, and P-tau181P analysis using
ELISA
CSF analyses of Ab1–42, T-tau, and P-tau181P were per-
formed by means of ELISA, as part of a clinical diagnostic
workup. Cutoff values were derived from the lower and upper
detection limits inherent to the ELISA kits (INNOTEST
b amyloid(1–42), INNOTEST hTAU-Ag, and INNOTEST
PHOSPHO-TAU(181P) for CSF Ab1–42, T-tau, and P-tau181P,
respectively [Fujirebio, Ghent, Belgium]), that is, 125 pg/mL
and 2000 pg/mL for Ab1–42, 75 pg/mL and 1200 pg/mL for T-
tau, and 15.6 pg/mLand500pg/mL for P-tau181P. Thedetailed
CSF analysis protocol has already been published by Le
Bastard et al. [37].
2.4. Reversed-phase high-performance liquid
chromatography with electrochemical detection
Tryptophan and the monoamines, dopamine (DA), seroto-
nin (5-HT), A and NA, as well as their respective metabolites
(homovanillic acid and 3,4-dihydroxyphenylacetic acid,
5-hydroxyindoleacetic acid [5-HIAA], and MHPG) were
analyzed in paired CSF-serum samples by means of an opti-
mized and validated reversed-phase high-performance liquid
chromatography system with electrochemical detection
(ALEXYS Monoamine Analyzer; Antec Leyden B.V., Zoe-Downloaded for Anonymous User (n/a) at Rijksuniversiteit Gronin
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was standardized and consisted of a precolumn purification
using Amicon Ultra 0.5 Centrifugal Filters (cutoff 3000 Da;
Millipore, Ireland), washed twice with 450 mL sample buffer
during centrifugation (14,000! g, 25 minutes, 4C). Subse-
quently, CSF and serum sampleswere loaded onto the prewet-
ted columns and centrifuged at 4C for 40 minutes at
14,000! g. Thefiltratewas diluted 1:2 and 1:7 forCSF,while
1:4 and 1:15 dilutions were implemented for serum. Finally,
diluted samples were injected automatically onto an ALF-
125 column (C18; 250 mm! 1.0 mm, 3 mm particle size).
Further specifications of the reversed-phase high-perfor-
mance liquid chromatographywith electrochemical detection
procedure have been described by Van Dam et al. [38].
2.5. Statistics
As our data set was characterized by non-normally distrib-
uted variables, nonparametric statistical testswere performed.
All continuous variables were tested for differences between
diagnostic classes using the Kruskal–Wallis test, followed by
a post hoc analysis using the Mann–Whitney U tests with a
Bonferroni correction for multiple comparisons (P , .005).
In addition, the association between the diagnostic classes
and categorical variables such as gender was tested using
the chi-square test. If the expected cell count was less than
five, Fisher’s exact test was used.
To identify the most discriminative indicators of disease
status, stepwise forward conditional logistic regression anal-
ysis was applied, with disease status as dependent variable
and a combination of standard AD biomarkers and mono-
amines or metabolites as explanatory variables. Age was
included in every regression model. Subsequently, area un-
der the curve (AUC) values belonging to the respective
ROC curves of models fitted with and without the addition
of monoamines and/or metabolites were compared by per-
forming DeLong tests. Finally, optimal cutoff values were
determined by maximization of the Youden’s index [39].
All statistical analyses, except for DeLong tests, were
performed using SPSS 24.0 for Windows (IBM SPSS Soft-
ware; IBM Corp, Armonk, NY). The DeLong test was car-
ried out as implemented in a ROC package for R, version
3.4.0 for Windows, specifically designed to investigate par-
tial AUC values (pROC). [40].3. Results
3.1. Demographical and clinical data
Table 1 contains corresponding demographical and clin-
ical information.
Whereas all patient groups were gender matched
(P 5 .174), age of CSF and serum sampling was only com-
parable between the AD and DLB/PDD groups (P 5 .519),
as well as between the AD and CONTR groups (P 5 .660)
and DLB/PDD and CONTR groups (P 5 .469). Further-
more, significant differences were detected for cognitivegen from ClinicalKey.com by Elsevier on March 29, 2018.
opyright ©2018. Elsevier Inc. All rights reserved.
Table 1
Demographic and clinical data of the study population
Parameter AD (n 5 52) FTD (n 5 59) DLB/PDD (n 5 53) CONTR (n 5 88) Y-CONTR (n 5 32) Test statistics





























N/A X2 5 84.2
P , .00001












N/A X2 5 40.1
P , .00001












N/A X2 5 53.9
P , .00001












N/A X2 5 48.2
P , .00001













































52/0 57/2 53/0 82/6 32/0 Fisher’s exact test 5 6.6
P 5 .078
NOTE. Data are represented as mean6 SD with minimum-maximum ranges between brackets. Test statistics of the Kruskal–Wallis and chi-square (or Fisher’s
exact) analysis can be found in the rightmost column, while statistically significant differences with P .005, P  .001, and P  .0001 after M-W U analysis with
post hoc Bonferroni corrections are depicted by one, two, or three superscript letters, respectively. Superscript letters denote differences between following groups, a:
AD and FTD, b: AD and DLB/PDD, c: AD and CONTR, d: AD and Y-CONTR, e: FTD and DLB/PDD, f: FTD and CONTR, g: FTD and Y-CONTR, h: DLB/PDD
and CONTR, i: DLB/PDD andY-CONTR, and j: CONTR andY-CONTR, respectively. Only cognitive test scores of nomore than 4months before date of sampling
were included in the analyses.
Abbreviations: AD, Alzheimer’s disease; BNT, Boston Naming Test; CONTR, controls; DLB/PDD, dementia with Lewy bodies/Parkinson’s disease demen-
tia; FTD, frontotemporal dementia; GDetS, Global Deterioration Scale; HDS, Hierarchic Dementia Scale; MMSE, Mini–Mental State Examination; N/A, not
applicable; VFT, Verbal Fluency Test; Y-CONTR, young controls.
J. Janssens et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 172-181 175test scores (P, .001) between all study groups. For instance,
Mini–Mental State Examination scores were much lower in
the AD group than those in DLB/PDD, FTD, and CONTR
groups. Indication of disease stage by global deterioration
scale scores indicated that AD patients were somewhat
more advanced than DLB/PDD and FTD counterparts.
Scores of the neuropsychological assessment were only
included if there were no more than 4 months between the
moment of testing and sampling. In total, 42 out of 52 AD,
15 out of 59 FTD, and, nine out of 53 DLB/PDD patients,
respectively, had neuropathological confirmation of their
clinical diagnoses. In addition, out of the nine neuropatho-
logically defined DLB patients, seven had concomitant AD
pathology.Downloaded for Anonymous User (n/a) at Rijksuniversiteit Gronin
For personal use only. No other uses without permission. CAdministered classes of psychotropic medication can be
found in Table 1 for each diagnostic category.3.2. Neurochemical comparisons of biomarkers and
monoamines
We found statistically significant differences in CSF levels
of Ab1–42 (P , .0001), T-tau (P , .0001), and P-Tau181P
(P5 .001) for the AD versus FTD comparison, as well as be-
tweenADandDLB/PDD (P5.001,P,.0001, andP,.0001
for Ab1–42, T-tau, and P-Tau181P, respectively), as well as be-
tween the AD and Y-CONTR groups (P, .0001 for all three
biomarkers). Differences in concentrations of Ab1–42
(P , .0001) and T-tau (P , .0001), but not P-Tau181Pgen from ClinicalKey.com by Elsevier on March 29, 2018.
opyright ©2018. Elsevier Inc. All rights reserved.
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significant. A complete description of biomarker levels be-
tween diagnostic categories can be found in Table 2.
Similar analyses were performed in paired CSF and serum
samples, taking into account all monoamines, their metabo-
lites, and calculated ratios. In CSF, we found 48 significant
differences between diagnostic categories, whereas 59 statis-
tically significant distinctions could be identified in serum.
Most of these differences were identified in the noradrenergic
system and, therefore, we will only focus on MHPG in CSF
and serum (Fig. 1). Significant differences in CSF MHPG
were found when we compared all diagnostic categories
(for all: P , .0001), except for the comparisons between
AD and FTD, AD and CONTR, and FTD and CONTR. Like-
wise, distinct serum MHPG levels could be observed for all
group comparisons (P  .001), other than those between
AD and FTD and AD and CONTR.
We refer to the Supplementary Table for the complete
data set of CSF and serum monoamines for each diagnostic
category.
3.3. Added value of monoamines on standard biomarkers
Table 3 contains diagnostic accuracy values correspond-
ing to each fitted model.
Besides the classic CSF biomarker set for AD, that is,
Ab1–42, T-tau, and P-Tau181P, as well as age of sampling,
CSF and serum NA and its metabolite MHPG were among
the most predictive markers. In case of distinctions between
AD and DLB/PDD, we found that the AUC values differed
significantly (P , .001) between the fitted models with and
without addition of CSF (P , .001) and serum (P 5 .001)
MHPG. When concentrations of only CSF and serum
MHPG were included in a model without the classic AD
biomarker panel, this difference could even be maintained
(P 5 .002). Subanalysis in the group of neuropathologically
characterized AD (n 5 42) and DLB (n 5 9) subjects
confirmed previous finding, with the AUC value increasingTable 2
Concentrations of classic CSF AD biomarkers
Parameter AD (n 5 52) FTD (n 5 59) DLB/PD





























NOTE. Data represented as mean6 SD with minimum-maximum ranges betwe
rightmost column, while statistically significant differences with P .005, P .00
(P .0125) are depicted by one, two, and three superscript letters, respectively. Sup
b: AD and DLB/PDD, c: AD and CONTR, and, d: AD and Y-CONTR, respective
Abbreviations: Ab1–42, amyloid b peptide of 42 amino acids; AD, Alzheimer’s
son’s disease dementia; FTD, frontotemporal dementia; P-tau181P, tau phosphoryl
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MHPG were included in the model instead of the core CSF
AD biomarkers. Models fitted for comparisons between the
AD group and both the FTD and CONTR groups could not
be significantly improved by addition of CSF or serum mo-
noamines. When an overall distinction between AD and
non-AD was made, the model with addition of CSF NA
(P 5 .002), serum 5-HIAA (P 5 .015), and CSF tryptophan
(P 5 .020) was characterized by a significantly raised
AUC (P5 .004). Finally, none of the distinctions including
Y-CONTR could be improved by addition of monoamines
and/or metabolites, as sensitivity and specificity values
already reached 100%.
3.4. Psychotropic medication comparisons: Effect on
monoamines
Concerning the influence of medication on monoamin-
ergic compounds, we found an expected effect of antidepres-
sants on serotonergic compounds and ratios in all diagnostic
categories except Y-CONTR. Significant differences could
also be detected in DA levels in FTD (serum DA;
P 5 .035) and DLB/PDD (CSF DA; P 5 .004) between pa-
tients taking and not taking anti-Alzheimer’s medication.
Overall, concentrations of DAwere altered between patients
taking and not taking psychotropic medication in CSF sam-
ples of the FTD group (P 5 .012) and serum samples of the
DLB/PDD group (P 5 .025). In addition, noradrenergic al-
terations could be observed between patients on anti-Parkin-
son’s medication and patients free of such medication, with
CSF MHPG/NA ratios being significantly higher in patients
not taking anti-Parkinson’s drugs in AD (P 5 .048) and
DLB/PDD groups (P 5 .005). Likewise, serum MHPG/NA
ratios in DLB/PDD subjects were higher in patients not tak-
ing anti-Parkinson’s drugs (P , .0001). In the same study
group, CSF and serum NA levels were higher (P 5 .002
and P, .0001, respectively), in patients free of anti-Parkin-


































en brackets. Test statistics of the Kruskal–Wallis analysis can be found in the
1, and P .0001 after M–WU analysis with Bonferroni post hoc corrections
erscript letters denote differences between following groups, a: AD and FTD,
ly.
disease; CONTR, controls; DLB/PDD, dementia with Lewy bodies/Parkin-
ated at threonine 181; T-tau, total tau; Y-CONTR, young controls.
gen from ClinicalKey.com by Elsevier on March 29, 2018.
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Fig. 1. CSFand serumMHPGlevels in all diagnostic categories.Data are rep-
resented asmedian6 IQR. Significant differences between groups afterM-W
U tests with post hoc Bonferroni correction (P , .005) are indicated by one
(P5 .001) or two asterisks (P, .001). Abbreviations: AD, Alzheimer’s dis-
ease; CONTR, controls; CSF, cerebrospinal fluid; DLB/PDD, dementia with
Lewy bodies/Parkinson’s disease dementia; FTD, frontotemporal dementia;
IQR, interquartile range; MHPG, 3-methoxy-4-hydroxyphenylglycol; M-W
U, Mann–Whitney U; S, serum; Y-CONTR, young controls.
J. Janssens et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 172-181 177significantly influenced CSF (P 5 .015) and serum
(P 5 .034) NA levels in the DLB/PDD group, as well as
CSF (P 5 .027) and serum (P 5 .022) MHPG/NA ratios.
4. Discussion
Similar to our results, CSF MHPG was reported to in-
crease discriminative power between AD andDLB, although
this effect was not apparent in comparisons with other de-
mentia types [15,16]. Besides monoamines in CSF, weTable 3
Results of DeLong tests indicating discriminative power between distinct diagnos
BM-based discrimination between Selected CSF BM Selected CS
Without MA-MT
AD and FTD Ab1–42/P-tau181P ratio* N/A
AD and DLB/PDD Ab1–42, T-tau & P-tau181P N/A
AD and CONTR Ab1–42/T-tau ratio* N/A
AD versus non-AD Ab1–42, T-tau & P-tau181P N/A
With inclusion of MA-MT
AD and FTD Ab1–42/P-tau181P ratio* CSF NA




AD and CONTR Ab1–42/T-tau ratio* CSF NA
AD versus non-AD Ab1–42, T-tau & P-tau181P CSF NA &
NOTE. Optimal cutoff values were determined by maximizing the Youden’s
significance: aP , .005; aaP , .001. An asterisk indicates the inclusion of bioma
AD and both FTD and CONTR, as described earlier in Struyfs et al. [41].
Abbreviations: 5-HIAA, 5-hydroxyindoleacetic acid; Ab1–42, amyloid b peptid
BM, biomarkers; CI, confidence interval; CONTR, controls; CSF, cerebrospinal fl
FTD, frontotemporal dementia; MHPG, 3-methoxy-4-hydroxyphenylglycol; MA&
P-tau181P, tau phosphorylated at threonine 181; S, sensitivity; Sp, specificity; TRP
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equally serve as valuable blood biomarkers. Indeed,
addition of serum MHPG and 5-HIAA proved to be useful
in discriminating AD versus non-AD, increasing sensitivity
and specificity values. Several studies have already indicated
that noradrenergic cell loss in the LC is apparent in both AD
[42–44] and DLB/PDD [45,46]. Although both dementias
are characterized by LC degeneration, cell loss in the
brainstem has been reported to be more prominent in DLB/
PDD [47]. The authors found a significantly lower number
of tyrosine-hydroxylase labeled neurons at the 70% level of
the LC in DLB patients compared with their AD counter-
parts, with the most rostral (0%) section defined as the begin-
ning of the trochlear nucleus, and themost caudal end defined
as the rostral edge of the trigeminal motor nucleus [48].
Moreover, two other studies also reported more severe, albeit
not significant, cell loss in DLB/PDD compared with AD
[45,46]. Further evidence supporting these findings can be
found in the fact that the LC is initially involved in DLB/
PDD neuropathology, while AD patients at first show Ab
plaques in neo- and allocortical brain regions, with amyloid
pathology only reaching the brainstem nuclei in more
advanced stages, that is, Thal stages 4 and 5 [49,50]. Tau
pathology affects brainstem nuclei only in mid-to-late AD
stages, coinciding with Braak stages IV–VI [51,52]. Most
patients suffering from DLB, as well as about half of PDD
subjects, also showAD pathology [53], possibly exacerbated
by the notion that the A53T mutant of a-synuclein, although
rare [54], is able to promote the association of tau fibrils [55].
Taken together, these factors might result in a more severe
noradrenergic cell loss in the LC due to a heavier neuropath-
ological load. It was shown that in patients suffering from
AD, this cell loss corresponded with an increased noradren-
ergic turnover (as a compensatory mechanism) in brain areas
receiving efferent projections from the LC [20,56], such as
the hippocampus and amygdala [57]. Our results supporttic categories
F and/or serum MA or MT AUC 95% CI S (%) Sp (%)
0.81 0.73–0.90 66 85
0.82a(a) 0.73–0.91 88 73
0.88 0.75–1.00 89 82
0.87a 0.80–0.94 90 76











0.94 0.88–1.0 89 92
TRP and serum 5-HIAA 0.95a 0.91–0.99 97 82
index. Superscript letters “a” added to the AUC values indicate statistical
rker ratios rather than separate biomarker levels for comparisons between
e of 42 amino acids; AD, Alzheimer’s disease; AUC, area under the curve;
uid; DLB/PDD, dementia with Lewy bodies/Parkinson’s disease dementia;
MT, monoamines andmetabolites; N/A, not applicable; NA, noradrenaline;
, tryptophan; T-tau, total tau.
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MHPG/NA ratios, indicating increased noradrenergic turn-
over, in both conditions. Furthermore, we observed that these
ratios were higher in DLB compared with AD patients
(Supplementary Table). Latter event might be explained by
amore severe neuropathological load inDLBpatients, result-
ing in a more extensive compensatory mechanism.
Although a preceding study questioned the use of CSF
MHPG as a reliable indicator of central noradrenergic activ-
ity given the diffusion of MHPG into spinal cord tissue [32],
it was suggested that both CSF NA and MHPG levels re-
flected NA metabolism in the brain [20,33,58,59], while
plasma NA was hypothesized to mirror noradrenergic
turnover of peripheral sympathetic neurons [20,60]. A
more recent study confirmed that MHPG, unlike NA [20],
passes the blood–brain, as well as the blood-CSF barrier
[61], thus strengthening latter theory. Still others suggested
that degeneration of peripheral noradrenergic neurons may
occur as a prodromal state of DLB and Parkinson’s disease
[62,63], preceding neuropathological lesions in the LC.
Another study reported that patients originally diagnosed
with pure autonomic failure may later on convert to
multiple system atrophy or DLB/PDD [63,64]. Our results
indeed indicated lowered NA and increased MHPG levels
in the CSF of the DLB/PDD group, possibly reflecting the
hypothesis that extensive damage to the LC results in
lowered and increased brain NA and MHPG levels,
respectively, which are mirrored in the CSF of these
patients. In AD, we found a trend toward increased CSF
MHPG levels, in addition to significantly decreased NA
levels compared with CONTR.
The direction of change of NA andMHPG levels has been
the subject of previous debate. For instance, levels of CSF
NA and MHPG were found to be unchanged or enhanced
in patients suffering from (severe) AD [16,20,65]. It has
also been reported that CSF MHPG levels were unchanged
or decreased in PDD [66] and decreased in DLB patients
[16]. However, CSF NA levels between AD and DLB/
PDD patients did not differ, which was in concordance
with previous findings [36]. We hypothesize that we could
not corroborate previous findings regarding CSF NA
because this compound was influenced by several types of
psychotropic medication in the DLB/PDD group, while little
information pertaining to medication effects is provided in
the study conducted by Herbert et al. (2014). Lastly, next
to the proposed hypothesis, differences in study population
characteristics and a considerable variation in CSF MHPG
levels in the DLB group reported by Herbert et al. (2014),
might also have caused this discrepancy compared with pre-
ceding studies. In serum, both diagnostic categories showed
increased MHPG and NA concentrations, which may be ex-
plained by additional NA release by peripheral noradren-
ergic neurons, as well as peripheral NA metabolism.
Conversely, patients suffering from pure autonomic failure
are characterized by lowered plasma NA levels [63], as a
result of autonomic dysfunction. This finding could not beDownloaded for Anonymous User (n/a) at Rijksuniversiteit Gronin
For personal use only. No other uses without permission. Ccorroborated in our study, possibly because serum is a large
compartment in which several confounding biological
processes occur, possibly masking previously mentioned
effects.
One of the limitations of this study is the variation of sam-
pling procedures in the control group, which could give rise
to a considerable amount of variation in serumMHPG levels
in this population (Fig. 1). In addition, the biochemical anal-
ysis of MHPG and NA, which are sensitive to preanalytical
variability effects of temperature and oxidation, still remains
challenging. We also found that medication use was not
comparable between diagnostic categories, and, moreover,
that psychotropic drug use might have influenced various
monoaminergic compounds, such as the serotonergic and
noradrenergic ones (see section 3.4). However, it should be
taken into account that none of the serotonergic parameters
influenced by antidepressant medication were included in
the logistic regression models, with the sole exception of
serum 5-HIAA for the distinction between AD and non-
AD. Finally, none of the drug classes influenced concentra-
tions of serum nor CSFMHPG, a crucial compound included
in the newly fitted models. This is a strength of the study in
addition to the considerable amount of available clinical and
neuropsychological data, as well as the additional neuro-
pathological confirmation.5. Conclusion
We observed that CSF and serum monoamines have an
added value in the differential diagnosis of dementia, next
to the classical CSF AD biomarker panel. In particular, we
found that CSF and serum MHPG were the most valuable
markers to discriminate DLB/PDD from AD. To verify these
findings, future studies should focus on age-matched, and,
preferably, medication-free patient populations. Before-
hand, various methodological and confounding aspects
that might interfere with the analysis of CSF/serum
MHPG, such as sample handling, lumbar puncture, and die-
tary effects, should be vigorously investigated.Acknowledgments
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1. Systematic review: The establishment of dementia
biomarkers in body fluids still faces difficulties. Previ-
ous work led to the discovery that cerebrospinal fluid
(CSF) and serum 3-methoxy-4-hydroxyphenylglycol
(MHPG) levels are altered in Alzheimer’s disease
(AD) and dementia with Lewy bodies/Parkinson’s
disease dementia patients and that addition of CSF
MHPG to the AD biomarker panel improved diag-
nostic accuracy betweenAD and dementia with Lewy
bodies/Parkinson’s disease dementia.
2. Interpretation: Our findings confirmed the added value
of CSF MHPG in distinguishing AD and dementia
with Lewy bodies/Parkinson’s disease dementia, and,
moreover, extended this conclusion to serum MHPG.
These results correspond to the distinct degrees of
neuropathological damage to the locus coeruleus.
3. Future directions: To corroborate our conclusion, it is
advisable that forthcoming studies investigate larger,
fully neuropathologically characterized, medication-
free patient populations. The quantification of the
degree of locus coeruleus neuronal loss combined
with CSF and serum MHPG analyses in various de-
mentia subgroups might strengthen this hypothesis.References
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